New guidance provides clear advice to reduce medication errors in anesthesia care

Through the acquisition, Bristol Myers Squibb will be able to diversify its oncology portfolio with targeted therapies such as Krazati. Credit: nitpicker via Shutterstock. On

Ten com­pa­nies are now com­pet­ing for mar­ket share with Ab­b­Vie’s megablock­buster rheuma­toid arthri­tis drug Hu­mi­ra (adal­i­mum­ab), but two of those com­peti­tors — Pfiz­er and Boehringer